Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer

Clinical Trial ID NCT01349959

Rank	Title	Journal	Year	PubWeight™‹?›
1	Epigenetic protein families: a new frontier for drug discovery.	Nat Rev Drug Discov	2012	6.70
2	New strategies for triple-negative breast cancer--deciphering the heterogeneity.	Clin Cancer Res	2014	1.65
3	Emerging targeted agents in metastatic breast cancer.	Nat Rev Clin Oncol	2013	1.59
4	Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers.	Oncotarget	2014	1.47
5	Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.	Pharmgenomics Pers Med	2014	1.09
6	Triple-negative breast cancer: are we making headway at least?	Ther Adv Med Oncol	2012	1.01
7	Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice.	J Adv Pract Oncol	2015	0.89
8	γδ T cells and epigenetic drugs: A useful merger in cancer immunotherapy?	Oncoimmunology	2015	0.87
9	Epigenetic Therapeutics: A New Weapon in the War Against Cancer.	Annu Rev Med	2016	0.87
10	Genomic and Epigenomic Alterations in Cancer.	Am J Pathol	2016	0.86
11	Biology and Management of Patients With Triple-Negative Breast Cancer.	Oncologist	2016	0.84
12	Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.	Breast Cancer Res	2014	0.81
13	Role of epigenetic modifications in luminal breast cancer.	Epigenomics	2015	0.76